DREaM Study: Updated Analysis Characterizing Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder

Poster A106, Monday, October 8, 11:30 am - 1:00 pm, Essex Ballroom

Brianne Brown1, Ibrahim Turkoz2, Edward Kim1, Larry Alphs1; 1Janssen Scientific Affairs, LLC, Titusville, NJ, 2Janssen Research and Development, LLC, Titusville, NJ

The Disease Recovery Evaluation and Modification (DREaM) trial (NCT02431702) compares the effectiveness of treatment with paliperidone palmitate long-acting injection versus oral antipsychotics in subjects with recent-onset schizophrenia. This analysis characterized demographics and clinical characteristics of DREaM enrollees and compared similar data from the Recovery After an Initial Schizophrenia Episode (RAISE) study in subjects with first-episode psychosis. Characteristics were evaluated using descriptive statistics and study comparisons were evaluated using chi-square test and t-tests. As of January 2018, 222 subjects were enrolled in DREaM and 404 subjects were available from RAISE. Mean±SD ages for the DREaM and RAISE studies were comparable (23.2±4.5 vs 23.1±5.1 years; P=0.956); the proportion of males was similar (76% vs 73%; P=0.320), as were the baseline CGI-S scores (4.1±1.0 vs 4.1±0.8; P=0.179). More subjects in DREaM lived with family/friends compared with those in RAISE (87% vs 71%; P<0.001). The majority of DREaM subjects had a schizophrenia diagnosis (76%) and were enrolled 12.4±7.4 months after their first psychotic episode, with 1.1±1.1 psychiatric hospitalizations. Histories of antipsychotic exposure, categorized as <6 months, 6-12 months, and >12 months, were 49%, 19%, and 21%, respectively. The Clinician-Rated Dimensions of Psychosis Symptom Severity scale showed that symptoms were most severe in the domains of “negative symptoms” and “delusions.” Data on the fully enrolled study population will be available at the time of presentation. With few exceptions, the baseline demographics and characteristics of subjects in DREaM appear similar to those in the RAISE study and are representative of recently diagnosed patients with schizophrenia.

Topic Area: Psychopharmacology

Back to Poster Schedule